-
公开(公告)号：US20240358756A1
公开(公告)日：2024-10-31
申请号：US18599924
申请日：2024-03-08
发明人： Ricarda HANNEN , Jens HUKELMANN , Florian KOEHLER , Daniel Johannes KOWALEWSKI , Heiko SCHUSTER , Oliver SCHOOR , Michael ROEMER , Chih-Chiang TSOU , Jens FRITSCHE
IPC分类号： A61K35/17 , A61K39/00 , A61P35/00 , C07K14/47 , C12N5/0783
CPC分类号： A61K35/17 , A61K39/0011 , A61P35/00 , C07K14/4748 , C12N5/0636
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240299455A1
公开(公告)日：2024-09-12
申请号：US18599860
申请日：2024-03-08
发明人： Ricarda HANNEN , Jens HUKELMANN , Florian KOEHLER , Daniel Johannes KOWALEWSKI , Heiko SCHUSTER , Oliver SCHOOR , Michael ROEMER , Chih-Chiang TSOU , Jens FRITSCHE
IPC分类号： A61K35/17 , A61K39/00 , A61P35/00 , C07K14/47 , C12N5/0783
CPC分类号： A61K35/17 , A61K39/0011 , A61P35/00 , C07K14/4748 , C12N5/0636
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240269184A1
公开(公告)日：2024-08-15
申请号：US18606764
申请日：2024-03-15
发明人： Ricarda HANNEN , Jens HUKELMANN , Florian KOEHLER , Daniel Johannes KOWALEWSKI , Heiko SCHUSTER , Oliver SCHOOR , Michael ROEMER , Chih-Chiang TSOU , Jens FRITSCHE
IPC分类号： A61K35/17 , A61K39/00 , A61P35/00 , C07K14/47 , C12N5/0783
CPC分类号： A61K35/17 , A61K39/0011 , A61P35/00 , C07K14/4748 , C12N5/0636
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240166717A1
公开(公告)日：2024-05-23
申请号：US18433940
申请日：2024-02-06
发明人： Jens HUKELMANN , Heiko SCHUSTER , Lena WULLKOPF , Christoph SCHRAEDER , Jens FRITSCHE , Daniel Johannes KOWALEWSKI , Michael ROEMER , Oliver SCHOOR
IPC分类号： C07K14/725 , A61K35/17 , C07K14/74 , C07K16/28
CPC分类号： C07K14/7051 , A61K35/17 , C07K14/70539 , C07K16/2833 , A61K38/00
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240166713A1
公开(公告)日：2024-05-23
申请号：US18433894
申请日：2024-02-06
发明人： Jens HUKELMANN , Heiko SCHUSTER , Lena WULLKOPF , Christoph SCHRAEDER , Jens FRITSCHE , Daniel Johannes KOWALEWSKI , Michael ROEMER , Oliver SCHOOR
IPC分类号： C07K14/725 , A61K35/17 , A61K38/00 , C07K14/74 , C07K16/28
CPC分类号： C07K14/7051 , A61K35/17 , C07K14/70539 , C07K16/2833 , A61K38/00 , C07K2319/30
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240158460A1
公开(公告)日：2024-05-16
申请号：US18421968
申请日：2024-01-24
发明人： Jens HUKELMANN , Heiko SCHUSTER , Lena WULLKOPF , Christoph SCHRAEDER , Jens FRITSCHE , Daniel Johannes KOWALEWSKI , Michael ROEMER , Oliver SCHOOR
IPC分类号： C07K14/725 , A61K35/17 , C07K14/74 , C07K16/28
CPC分类号： C07K14/7051 , A61K35/17 , C07K14/70539 , C07K16/2833 , A61K38/00 , C07K2319/30
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
7.发明公开公开(公告)号：US20240123044A1
公开(公告)日：2024-04-18
申请号：US18490581
申请日：2023-10-19
发明人： Toni WEINSCHENK , Oliver SCHOOR , Andrea MAHR
IPC分类号： A61K39/00 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/705 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886
CPC分类号： A61K39/0011 , C07K7/06 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K14/70503 , C07K16/2803 , C07K16/2833 , C07K16/30 , C12N5/0638 , C12N15/115 , C12Q1/6886 , A61K2039/5158 , A61K2039/572 , A61K2039/80 , C07K2317/32 , C07K2319/40 , C12N2310/16 , C12N2501/50 , C12Q2600/156 , C12Q2600/158
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
8.发明公开公开(公告)号：US20240083969A1
公开(公告)日：2024-03-14
申请号：US18321820
申请日：2023-05-23
发明人： Heiko SCHUSTER , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH , Gisela SCHIMMACK , Michael ROEMER
IPC分类号： C07K14/725 , A61K9/19 , A61K35/17 , A61K39/00 , A61P35/00 , C07K14/74 , C07K16/28 , C12N5/0783 , C12N15/115 , G01N33/574 , G16B25/10
CPC分类号： C07K14/7051 , A61K9/19 , A61K35/17 , A61K39/001111 , A61P35/00 , C07K14/70539 , C07K16/2809 , C07K16/2833 , C12N5/0638 , C12N15/115 , G01N33/57492 , G16B25/10 , A61K38/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20240067697A1
公开(公告)日：2024-02-29
申请号：US18489600
申请日：2023-10-18
发明人： Jens HUKELMANN , Heiko SCHUSTER , Lena WULLKOPF , Christoph SCHRAEDER , Jens FRITSCHE , Daniel Johannes KOWALEWSKI , Michael ROEMER , Oliver SCHOOR
IPC分类号： C07K14/725 , A61K35/17 , C07K14/74 , C07K16/28
CPC分类号： C07K14/7051 , A61K35/17 , C07K14/70539 , C07K16/2833 , A61K38/00
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO:1 to SEQ ID NO:113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
10.发明公开公开(公告)号：US20240016913A1
公开(公告)日：2024-01-18
申请号：US18458233
申请日：2023-08-30
发明人： Jens HUKELMANN , Heiko SCHUSTER , Ricarda HANNEN , Christoph SCHRAEDER , Jens FRITSCHE , Franziska HOFFGAARD , Daniel Johannes KOWALEWSKI , Oliver SCHOOR
IPC分类号： A61K39/00 , A61P35/00 , C07K14/705 , C07K14/74
CPC分类号： A61K39/0011 , A61P35/00 , C07K14/705 , C07K14/70539 , A61K39/00 , A61K2039/5158
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
搜索结果
601 条记录 (耗时 0.038 秒)
